US Firms to Drop Weight Loss Drugs
About fourteen percent of US employers plan to drop GLP-1 weight loss drugs by 2027 as healthcare costs continue to rise. Survey data shows increasing utilization and high prices are driving companies to rethink their health benefits.
Xurve View
Insights:
Xurve View
About 14% of employers in the United States plan to drop GLP-1 weight-loss drugs by 2027 as corporate healthcare costs climb. Total employer healthcare spending is projected to rise 9.2% in 2027 if firms make no cost adjustments, up from an 8.5% increase in 2026. The rising utilization of branded treatments from Eli Lilly & Co and Novo Nordisk A/S-B has driven corporations to tighten pharmacy benefits.
